130 related articles for article (PubMed ID: 15494296)
41. Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
Bowen DT
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S16-23. PubMed ID: 16085013
[TBL] [Abstract][Full Text] [Related]
42. Epigenetic regulation: a new research area for melatonin?
Korkmaz A; Reiter RJ
J Pineal Res; 2008 Jan; 44(1):41-4. PubMed ID: 18078446
[TBL] [Abstract][Full Text] [Related]
43. New approaches to the treatment of myelodysplasia.
List AF
Oncologist; 2002; 7 Suppl 1():39-49. PubMed ID: 11961208
[TBL] [Abstract][Full Text] [Related]
44. Life after hypomethylating agents in myelodysplastic syndrome: new strategies.
Santini V
Curr Opin Hematol; 2015 Mar; 22(2):155-62. PubMed ID: 25603477
[TBL] [Abstract][Full Text] [Related]
45. Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Gore SD
J Natl Compr Canc Netw; 2006 Jan; 4(1):83-90. PubMed ID: 16403407
[TBL] [Abstract][Full Text] [Related]
46. Differentiation therapy for myelodysplastic syndrome.
Hofmann WK; Koeffler HP
Clin Cancer Res; 2002 Apr; 8(4):939-41. PubMed ID: 11948096
[No Abstract] [Full Text] [Related]
47. [Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk myelodysplastic syndrome].
Maeda Y
Rinsho Ketsueki; 2014 Oct; 55(10):1870-81. PubMed ID: 25297751
[No Abstract] [Full Text] [Related]
48. [Application of DNA methyltransferase inhibitors for myelodysplastic syndrome].
Lü XY; Du YX; Dai ZH; Liu M; Liu XY; Zhang KL
Yi Chuan; 2013 Feb; 35(2):136-40. PubMed ID: 23448925
[TBL] [Abstract][Full Text] [Related]
49. Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.
Lyons J; Bayar E; Fine G; McCullar M; Rolens R; Rubinfeld J; Rosenfeld C
Curr Opin Investig Drugs; 2003 Dec; 4(12):1442-50. PubMed ID: 14763130
[TBL] [Abstract][Full Text] [Related]
50. Clinical roundtable monograph. Choosing an appropriate therapy for lower-risk MDS in the community setting.
Lyons RM
Clin Adv Hematol Oncol; 2009 Jul; 7(7):S5-7. PubMed ID: 19731464
[No Abstract] [Full Text] [Related]
51. DNA methyltransferase inhibitors: class effect or unique agents?
Griffiths EA; Gore SD
Leuk Lymphoma; 2008 Apr; 49(4):650-1. PubMed ID: 18398728
[No Abstract] [Full Text] [Related]
52. PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes.
Follo MY; Finelli C; Bosi C; Martinelli G; Mongiorgi S; Baccarani M; Manzoli L; Blalock WL; Martelli AM; Cocco L
Leukemia; 2008 Jan; 22(1):198-200. PubMed ID: 17625605
[No Abstract] [Full Text] [Related]
53. The role of methyltransferase inhibitors in the management of the myelodysplastic syndromes.
Silverman LR
Cancer Control; 2004; 11(6 Suppl):11-5. PubMed ID: 15625532
[No Abstract] [Full Text] [Related]
54. New drug for bone marrow disease.
FDA Consum; 2004; 38(4):7. PubMed ID: 15346573
[No Abstract] [Full Text] [Related]
55. Clinical effectiveness of decitabine in severe sickle cell disease.
Saunthararajah Y; Molokie R; Saraf S; Sidhwani S; Gowhari M; Vara S; Lavelle D; DeSimone J
Br J Haematol; 2008 Apr; 141(1):126-9. PubMed ID: 18324975
[No Abstract] [Full Text] [Related]
56. Differentiation-inducing agents in the treatment of myelodysplastic syndromes.
Kizaki M; Koeffler HP
Semin Oncol; 1992 Feb; 19(1):95-105. PubMed ID: 1371019
[No Abstract] [Full Text] [Related]
57. Methyltransferase inhibitors: changing the treatment algorithm for myelodysplastic syndromes.
List A
Cancer Control; 2004; 11(6 Suppl):16-9. PubMed ID: 15625533
[No Abstract] [Full Text] [Related]
58. Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine.
McCormack SE; Warlick ED
Onco Targets Ther; 2010 Sep; 3():157-65. PubMed ID: 20856790
[TBL] [Abstract][Full Text] [Related]
59. Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes.
Mahadevan D; Sutton GR
Expert Opin Investig Drugs; 2015 May; 24(5):725-33. PubMed ID: 25724698
[TBL] [Abstract][Full Text] [Related]
60. Epigenetics: Showing a more sensitive side.
McCarthy N
Nat Rev Cancer; 2013 Oct; 13(10):680. PubMed ID: 24030504
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
